{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994302536064.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00535-003-1098-7"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-003-1098-7.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00535-003-1098-7/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-003-1098-7"}},{"identifier":{"@type":"PMID","@value":"12825127"}}],"dc:title":[{"@value":"Propagermanium: a nonspecific immune modulator for chronic hepatitis B"}],"description":[{"notation":[{"@value":"Although antiviral agents have been adopted for the management of chronic hepatitis B, they have only limited efficacy because of the underlying impaired immune status. Propagermanium, a hydrophilic polymer of 3-oxygermyl propionate, has been reported to have potent immune modulatory activity associated with antiinflammatory and antineoplastic properties. For example, propagermanium augments lymphocyte functions in CD4 and CD8 cells, and in natural killer (NK) cells, and induces the production of several cytokines. A controlled pilot study of 16-week treatment with propagermanium for chronic hepatitis B (of moderate and mild grades on hepatic histology) revealed a sustained clearance of hepatitis B e (HBe) antigen and a favorable biochemical response at week 16 of treatment and at week 48 post-treatment. An open study also supported the clearance of hepatitis B virus from the blood and the possible improvement of histologic grading in the liver. There were few adverse events. A postmarketing survey, however, revealed the occurrence of moderate to severe liver damage after the treatment in about 4% of patients. Despite the exact nature of the liver damage being unclear, a putative cause is the swift removal of virus-infected hepatocytes by an immune reaction through the treatment. A subtle balance between host and viral conditions is the factor which most determines hepatitis B virus persistence. The rationale for a nonspecific immune modulator for the treatment of chronic hepatitis B will be the restoration of cellular immune responsiveness to viral infection. Although the cellular immunity for hepatitis B virus prior to the treatment should be studied, adequate observation of hepatic functions and viral markers in the recipients is clinically useful to predict liver failure during the treatment. In summary, the propagermanium regimen offers a potent and safe approach that is cost-effective for appropriate chronic hepatitis B patients with reserve hepatic capacity, and will provide new perspectives for immune therapy in chronic hepatitis B."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994302536068","@type":"Researcher","foaf:name":[{"@value":"Chisato Hirayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994302536065","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994302536064","@type":"Researcher","foaf:name":[{"@value":"Madoka Ito"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994302536066","@type":"Researcher","foaf:name":[{"@value":"Makoto Okumura"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994302536067","@type":"Researcher","foaf:name":[{"@value":"Toshitugu Oda"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09441174"},{"@type":"EISSN","@value":"14355922"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2003-06","prism:volume":"38","prism:number":"6","prism:startingPage":"525","prism:endingPage":"532"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-003-1098-7.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00535-003-1098-7/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-003-1098-7"}],"createdAt":"2018-06-12","modifiedAt":"2019-05-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Immunity,%20Cellular","dc:title":"Immunity, Cellular"},{"@id":"https://cir.nii.ac.jp/all?q=Interferon%20Inducers","dc:title":"Interferon Inducers"},{"@id":"https://cir.nii.ac.jp/all?q=Time%20Factors","dc:title":"Time Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Germanium","dc:title":"Germanium"},{"@id":"https://cir.nii.ac.jp/all?q=Alanine%20Transaminase","dc:title":"Alanine Transaminase"},{"@id":"https://cir.nii.ac.jp/all?q=Pilot%20Projects","dc:title":"Pilot Projects"},{"@id":"https://cir.nii.ac.jp/all?q=Liver%20Failure,%20Acute","dc:title":"Liver Failure, Acute"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Adjuvants,%20Immunologic","dc:title":"Adjuvants, Immunologic"},{"@id":"https://cir.nii.ac.jp/all?q=Double-Blind%20Method","dc:title":"Double-Blind Method"},{"@id":"https://cir.nii.ac.jp/all?q=Liver","dc:title":"Liver"},{"@id":"https://cir.nii.ac.jp/all?q=Organometallic%20Compounds","dc:title":"Organometallic Compounds"},{"@id":"https://cir.nii.ac.jp/all?q=Product%20Surveillance,%20Postmarketing","dc:title":"Product Surveillance, Postmarketing"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Propionates","dc:title":"Propionates"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232391244544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Propagermanium, a CCR2 inhibitor, attenuates cerebral ischemia/reperfusion injury through inhibiting inflammatory response induced by microglia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004233113835776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A Novel Extraction Method Based on a Reversible Chemical Conversion for the LC/MS/MS Analysis of the Stable Organic Germanium Compound Ge-132"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286995467423104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Potentials of C‐C motif chemokine 2–C‐C chemokine receptor type 2 blockers including propagermanium as anticancer agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286995467700608","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643858020864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568470444423808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug repositioning in cancer: The current situation in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092483302656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Synthesis of a Pentacoordinate Germanium Compound Possessing a γ-Lactone and a Dative-Bonding Carboxylic Acid"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230618759808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"“Elimination of Hepatitis by 2030”: Present Realities and Future Projections"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848655125726592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Structural Basis for Polymer Packing and Solvation Properties of the Organogermanium Crystalline Polymer Propagermanium and Its Derivatives"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567404898176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861295372465152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A hydrolysate of poly-trans-[(2-carboxyethyl)germasesquioxane] (Ge-132) suppresses Cav3.2-dependent pain by sequestering exogenous and endogenous sulfide"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861711969501824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Organogermanium THGP Induces Differentiation into M1 Macrophages and Suppresses the Proliferation of Melanoma Cells via Phagocytosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204902088448","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Metabolism of tellurium, antimony and germanium simultaneously administered to rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679408092416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"C-C Chemokine Receptor 2 Inhibitor Improves Diet-Induced Development of Insulin Resistance and Hepatic Steatosis in Mice"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-003-1098-7"},{"@type":"OPENAIRE","@value":"doi_dedup___::c26906a2484035cc4d79f04607fc5161"},{"@type":"CROSSREF","@value":"10.1111/cas.14075_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1111/cas.14306_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.37349/emed.2021.00058_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.3390/ijms24031885_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1016/j.redox.2022.102579_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1111/cas.14318_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.5551/jat.3368_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.3987/com-20-s(k)9_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1097/id9.0000000000000028_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1016/j.neuint.2019.02.010_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.2131/jts.34.295_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1021/ac504466u_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1002/edm2.159_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"},{"@type":"CROSSREF","@value":"10.1002/jps.24486_references_DOI_L3PzgFiR0daHegGjDstMb1XDi0y"}]}